PT-141
Bremelanotide, Vyleesi
A synthetic peptide analog of alpha-MSH used to treat hypoactive sexual desire disorder by activating melanocortin receptors to enhance sexual arousal.
Completed
PHASE2
NCT05709444
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Palatin Technologies, Inc
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT01382719
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT03973047
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
AMAG Pharmaceuticals, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04943068
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
Kwang Dong Pharmaceutical co., ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT02338960
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT06565611
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Palatin Technologies, Inc
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00425256
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Palatin Technologies, Inc
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06867835
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk
Cosette Pharmaceuticals, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT04179734
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Imperial College Healthcare NHS Trust
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT02333071
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc
INTERVENTIONAL
Updated Dec 15, 2025